申请人:The DuPont Merck Pharmaceutical Company
公开号:US05244917A1
公开(公告)日:1993-09-14
This invention relates to substituted naphthofurans as anti-inflammatory and anti-allergic agents, pharmaceutical compositions containing them, processes for their preparation, and their use as anti-inflammatory and anti-allergic agents. The naphthofurans are of the formula ##STR1## and pharmaceutically acceptable salts thereof wherein: R.sup.1 is CN or COOR.sup.9 ; R.sup.2 and R.sup.8 independently are H, C.sub.1 -C.sub.4 alkyl, COR.sup.9 or COR.sup.10 ; R.sup.3, R.sup.4, R.sup.6 and R.sup.7 are independently H, C.sub.1 -C.sub.4 alkyl, halogen, phenyl, CF.sub.3 or OR.sup.9 ; R.sup.5 is H, C.sub.1 -C.sub.4 alkyl, or COR.sup.9 ; and R.sup.9 and R.sup.10 are independently C.sub.1 -C.sub.4 alkyl, halogen or aryl.
这项发明涉及取代萘呋喃作为抗炎和抗过敏剂、含有它们的药物组合物、其制备过程以及作为抗炎和抗过敏剂的用途。这些萘呋喃的结构式为##STR1##及其药用盐,其中:R.sup.1为CN或COOR.sup.9;R.sup.2和R.sup.8独立地为H、C.sub.1 -C.sub.4烷基、COR.sup.9或COR.sup.10;R.sup.3、R.sup.4、R.sup.6和R.sup.7独立地为H、C.sub.1 -C.sub.4烷基、卤素、苯基、CF.sub.3或OR.sup.9;R.sup.5为H、C.sub.1 -C.sub.4烷基或COR.sup.9;R.sup.9和R.sup.10独立地为C.sub.1 -C.sub.4烷基、卤素或芳基。